title: Giant cavernous haemangioma: treatment with intralesional injection of OK-432.
abstract: Giant cavernous haemangioma was treated successfully with a new therapy consisting of intralesional injection of OK-432 (group A Streptococcus pyogenes of human origin). Complete regression was observed within 3 months without serious side effects except for fever of 2-3 days' duration and local inflammatory reaction lasting for 3-4 days. Local inflammatory reaction did not cause any damage to the overlaying skin and did not lead to scar formation.
authors.affiliation: Division of Surgery, Children's Research Hospital, Kyoto Prefectural University of Medicine, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Ogita
authors.forename: T
authors.initials: T
authors.lastname: Tsuto
authors.forename: E
authors.initials: E
authors.lastname: Deguchi
authors.forename: K
authors.initials: K
authors.lastname: Tokiwa
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
mesh_terms: D001688:Biological Products / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006392:Hemangioma, Cavernous / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007267:Injections; D010844:Picibanil / Q000008:administration & dosage*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013899:Thoracic Neoplasms / Q000188:drug therapy*
chemical_list: D001688:Biological Products; D010844:Picibanil